Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c

Jasper Therapeutics (NASDAQ: JSPR) reported Q2 EPS of ($0.10), $0.18 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Jasper Therapeutics (JSPR) click here.

You May Also Be Interested In

• Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
• AutoZone beats profit view but misses on revenue
• Raymond James Downgrades Baldwin Insurance (BWIN) to Underperform